Evidence from observational studies and association guidelines supports the use of sequential biologic therapy for these reasons. Owing to recent economic pressures on healthcare budgets ...
Kim Kelderman; Chief Executive Officer, Chief Operating Officer, Director; Bio-Techne Corp James Hippel; Chief Financial Officer, Executive Vice President - Finance; Bio-Techne Corp Good morning, and ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
If you’ve been on the internet recently, you’ve likely encountered Bryan Johnson’s meticulously optimized, data-driven quest ...
whereas patients aged 16 to 24 years are more likely to discontinue treatment of a type of biologic therapy due to ineffectiveness. Discontinuation of biologic therapies among patients with psoriasis ...
Inventia Life Science, an innovator in 3D cell culture technologies, announces the launch of RASTRUM™ Allegro, a ...
In part one of four, Dr Kevin Lustig and Dr Maria Thompson discuss the changing face of drug discovery and development and life science research in general.  , Outlining a process for research ...
"We will continue to build business models from cell therapy discovery to commercialization in order to optimize and democratize the global utilization of new therapies for patients." In the newly ...
Biological sciences encompasses all the divisions ... A small but in-depth study of allogeneic CAR T cell therapy in patients with high-risk neuroblastoma shows feasibility and potential efficacy ...
Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback